Results 1 to 10 of about 2,373 (170)

Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy [PDF]

Journal of Clinical Medicine
Neuroblastoma is a common childhood malignancy, and high-risk presentations, including an MYCN amplified status, continue to result in poor survival. Difluoromethylornithine (DFMO) is a new and well-tolerated treatment for high-risk neuroblastoma. This review article discusses preclinical and clinical data that resulted in the establishment of DFMO as ...
Joseph W Schramm
exaly   +4 more sources

DFMO inhibition of neuroblastoma tumorigenesis

Cancer Medicine
Background Most high‐risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event‐free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during ...
Divya Gandra, David H. Mulama, David M. Foureau, Kimberly Q. McKinney, Elizabeth Kim, Kaitlyn Smith, Jason Haw, Abhinav Nagulapally, Giselle L. Saulnier Sholler   +8 more
doaj   +3 more sources

Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [PDF]

Adv Sci (Weinh)
Chemotherapy‐induced efferocytosis drives ovarian cancer stem cell enrichment. By engulfing apoptotic cancer cells, macrophages upregulate ODC1 and produce putrescine, which elevates osteopontin (OPN) expression. Secreted OPN then activates the CD44 receptor on cancer cells, promoting stemness and chemoresistance.
Li W, Ying F, Pang X, Wu Q, Li G, Huang L, Xin J, Liu X, Liu P, Xu X, Tan S, Gao Y, Liu T, Sun S, Wang X, Wen Y, Cai L, Du S, Zhang Y, Cai J.   +19 more
europepmc   +2 more sources

Maintenance DFMO Increases Survival in High Risk Neuroblastoma [PDF]

Scientific Reports, 2018
AbstractHigh risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent ...
Giselle Saulnier Sholler, Peter Zage, William Ferguson   +2 more
exaly   +5 more sources

Difluoromethylornithine (DFMO) and AMXT 1501 inhibit capsule biosynthesis in pneumococci

Scientific Reports, 2022
Polyamines are small cationic molecules that have been linked to various cellular processes including replication, translation, stress response and recently, capsule regulation in Streptococcus pneumoniae (Spn, pneumococcus).
Moses B. Ayoola, Leslie A. Shack, Jung Hwa Lee, Juhyeon Lim, Hyungjin Eoh, Edwin Swiatlo, Otto Phanstiel, Bindu Nanduri   +7 more
doaj   +3 more sources

Thymoquinone and Difluoromethylornithine (DFMO) Synergistically Induce Apoptosis of Human Acute T Lymphoblastic Leukemia Jurkat Cells Through the Modulation of Epigenetic Pathways

Technology in Cancer Research and Treatment, 2020
Thymoquinone (TQ), a natural anticancer agent exerts cytotoxic effects on several tumors by targeting multiple pathways, including apoptosis. Difluoromethylornithine (DFMO), an irreversible inhibitor of the ornithine decarboxylase (ODC) enzyme, has shown
Syed Razvi, Mazin Zamzami, Hani Choudhry   +2 more
exaly   +2 more sources

Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection [PDF]

Viruses
Despite numerous research efforts and several effective vaccines and therapies developed against coronavirus disease 2019 (COVID-19), drug repurposing remains an attractive alternative approach for treatment of SARS-CoV-2 variants and other viral ...
Natalia A. Ignatenko, Hien T. Trinh, April M. Wagner, Eugene W. Gerner, Christian Bime, Chiu-Hsieh Hsu, David G. Besselsen   +6 more
doaj   +2 more sources

New insights for an old drug: difluoromethylornithine boosts the trypanocidal action of benznidazole on Trypanosoma cruzi in vitro and in vivo [PDF]

Frontiers in Cellular and Infection Microbiology
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is currently a global health problem. Its multiple forms of transmission, which favor the spread of the infection, and the limited treatment options—still restricted to only two drugs ...
Santiago José Martínez, Santiago José Martínez, María Cristina Vanrell, María Cristina Vanrell, Xiaomo Li, Carolina Carrillo, David M. Engman, Patricia Silvia Romano, Patricia Silvia Romano   +8 more
doaj   +2 more sources

High-dose DFMO alters protein translation in neuroblastoma. [PDF]

Neoplasia
ABSTRACT DFMO has been studied as a cancer therapeutic at doses ranging from 500-9,000 mg/m2/day. Lower doses are favored for cancer prevention studies while higher doses, often with chemotherapy, are studied in refractory cancers. DFMO inhibits the rate-limiting enzyme in polyamine synthesis, ornithine decarboxylase (
Franson AT, Liu K, Vemu R, Scadden E, Li Y, Vu A, Hogarty MD.   +6 more
europepmc   +4 more sources

The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma [PDF]

Molecular Oncology
High‐risk neuroblastomas, often associated with MYCN protooncogene amplification, are addicted to polyamines, small polycations vital for cellular functioning.
Mujahid Azfar, Weiman Gao, Chris Van den Haute, Lin Xiao, Mawar Karsa, Ruby Pandher, Ayu Karsa, Dayna Spurling, Emma Ronca, Angelika Bongers, Xinyi Guo, Chelsea Mayoh, Youri Fayt, Arthur Schoofs, Mark R. Burns, Steven H. L. Verhelst, Murray D. Norris, Michelle Haber, Peter Vangheluwe, Klaartje Somers   +19 more
doaj   +2 more sources